Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY:BDX)

170.86 +0.89 (+0.52%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software
Becton Dickinson and Co (NYSE: BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. 
Via Benzinga
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in... 
Via Benzinga
Why Embecta Stock Popped by Nearly 13% Today
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist. 
Via The Motley Fool
Looking Into Becton's Return On Capital Employed
Via Benzinga
What 6 Analyst Ratings Have To Say About Becton, Dickinson
Via Benzinga
A Bullish Sign Appears On Becton, Dickinson's Chart
Via Benzinga
What 6 Analyst Ratings Have To Say About Becton, Dickinson
Via Benzinga
2 Medical Stocks to Watch Heading Into 2023
The two healthcare companies easily outdid the S&P 500 this year. 
Via The Motley Fool
Embecta Stock Tumbles On Mixed Q4 Results, Softer Guidance
Via Benzinga
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products 
Via News Direct
Topics Economy
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the... 
Via Benzinga
Becton Dickinson, Freeport-McMoRan, GXO Logistics And This Mid-Cap ETF On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named iShares Core S&P Mid-Cap ETF (NYSE: IJH), saying that "mid-c 
Via Benzinga
What 4 Analyst Ratings Have To Say About Becton, Dickinson
Via Benzinga
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END 
Via FinancialNewsMedia
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
2 Relatively Safe Dividend Stocks to Buy Today and Hold Forever
They already have extensive track records of success, and there's even more on the way. 
Via The Motley Fool
2 Top Dividend Kings to Buy for the Long Haul
No matter how much changes, these two healthcare giants keep performing. 
Via The Motley Fool
Reliable Passive Income: an Analysis on Dividend Kings
A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company
Piper Sandler cut the price target on Becton, Dickinson and Company (NYSE: BDX) from $255 to $245. Piper Sandler analyst Jason Bednar maintained the stock with a Neutral. Becton, Dickinson shares... 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.41% on an annualized basis producing an average annual return of 11.05%. Currently, Becton, Dickinson has a market... 
Via Benzinga
Becton Dickinson's FY23 Guidance Trails Wall Street View Reflecting Foreign Currency Impact
Via Benzinga
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever
These healthcare companies should stay relevant for years as they continue to innovate with new products. 
Via The Motley Fool
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug 
Via MarketBeat
Topics Economy
BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
From BIOCORP
Via Business Wire
Becton Dickinson To Rally 23%? This Analyst Predicts $210 For NVIDIA
Citigroup cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $248 to $210. NVIDIA shares rose 1.2% to $118.12 on Tuesday. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Becton, Dickinson
Within the last quarter, Becton, Dickinson (NYSE:BDX) has observed the following analyst ratings: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.